Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study).

ABSTRACT

BACKGROUND: Lipoprotein-associated phospholipase A(2) (LpPLA(2)), also denoted as platelet-activating factor acetylhydrolase, is a lipoprotein-bound enzyme involved in inflammation and atherosclerosis. In this cohort study we investigated LpPLA(2) activity to predict cardiac mortality in patients scheduled for coronary angiography. METHODS: LpPLA(2) activity was determined in 2513 patients with and in 719 patients without angiographically confirmed coronary artery disease (CAD). RESULTS: During the median observation period of 5.5 years, 501 patients died. In patients with tertiles of LpPLA(2) activity of 420-509 U/L or >or=510 U/L, unadjusted hazard ratios (HRs) for cardiac death were 1.7 (95% CI 1.3-2.4; P = 0.001), and 1.9 (95% CI 1.4-2.5; P <0.001), respectively, compared with patients with LpPLA(2) activity risk factors and included angiographic CAD status, high-sensitivity C-reactive protein (hsCRP), and N-terminal pro-B-type natriuretic peptide, the 3rd tertile of LpPLA(2) activity predicted cardiac 5-year mortality with an HR of 2.0 (95% CI 1.4-3.1; P = 0.001). LpPLA(2) activity increased the adjusted risk for cardiac death by 2-fold in patients with hsCRP <3 mg/L in the 2nd (HR 2.4, 95% CI 1.4-4.2; P = 0.002) and 3rd (HR 2.1, 95% CI 1.1-4.0; P = 0.02) tertiles of LpPLA(2) activity and in patients with hsCRP of 3-10 mg/L in the 3rd tertile (HR 1.9, 95% CI 1.0-3.6; P = 0.03) of LpPLA(2) activity.

CONCLUSIONS:

LpPLA(2) activity predicts risk for 5-year cardiac mortality independently from established risk factors and indicates risk for cardiac death in patients with low and medium-high hsCRP concentrations. Therefore, LpPLA(2) activity may provide information for the identification and management of patients at risk beyond established risk stratification strategies.